Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for Lyell Immunopharma (LYEL) over the last 5 years, with Dec 2024 value amounting to $14.0 million.

  • Lyell Immunopharma's Shares Outstanding (Weighted Average) rose 50.09% to $19.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.2 million, marking a year-over-year increase of 50.09%. This contributed to the annual value of $14.0 million for FY2024, which is 9.89% up from last year.
  • According to the latest figures from FY2024, Lyell Immunopharma's Shares Outstanding (Weighted Average) is $14.0 million, which was up 9.89% from $12.7 million recorded in FY2023.
  • Lyell Immunopharma's 5-year Shares Outstanding (Weighted Average) high stood at $14.0 million for FY2024, and its period low was $12.0 million during FY2021.
  • For the 3-year period, Lyell Immunopharma's Shares Outstanding (Weighted Average) averaged around $13.0 million, with its median value being $12.7 million (2023).
  • Per our database at Business Quant, Lyell Immunopharma's Shares Outstanding (Weighted Average) decreased by 0.97% in 2021 and then rose by 9.89% in 2024.
  • Over the past 5 years, Lyell Immunopharma's Shares Outstanding (Weighted Average) (Yearly) stood at $12.1 million in 2020, then dropped by 0.97% to $12.0 million in 2021, then increased by 3.68% to $12.5 million in 2022, then climbed by 1.91% to $12.7 million in 2023, then climbed by 9.89% to $14.0 million in 2024.